Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P49961
UPID:
ENTP1_HUMAN
Alternative names:
Ecto-ATP diphosphohydrolase 1; Ecto-apyrase; Lymphoid cell activation antigen
Alternative UPACC:
P49961; A9Z1X8; B4DWB9; B4E1X1; B7Z599; G3XAF6; Q5T561; Q5T562; Q86VV3; Q9UQQ9; Q9Y3Q9
Background:
Ectonucleoside triphosphate diphosphohydrolase 1, also known as Ecto-ATP diphosphohydrolase 1, Ecto-apyrase, and Lymphoid cell activation antigen, plays a pivotal role in the nervous system. It hydrolyzes ATP and ADP to regulate purinergic neurotransmission and prevent platelet aggregation by converting platelet-activating ADP to AMP.
Therapeutic significance:
The protein's malfunction is linked to Spastic paraplegia 64, autosomal recessive, a neurodegenerative disorder. Understanding its role could lead to novel therapeutic strategies for managing this condition and potentially others involving purinergic signaling.